Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Status:
Terminated
Trial end date:
2007-11-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different
ways to stop tumor cells from dividing so they stop growing or die. Combining more than one
drug may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when
given with docetaxel in treating patients with metastatic prostate cancer.